Professor Munitta Muthana
Clinical Medicine, School of Medicine and Population Health
School Director of One University
Professor of Immuno-oncology
+44 114 215 9057
Full contact details
Clinical Medicine, School of Medicine and Population Health
D Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I joined the University of Sheffield in 2002 as a post-doctoral scientist in the Immunobiology Research Unit. From 2005 I held a research position in the Tumour Targeting Group where I was awarded funding as an independent researcher from the Prostate Cancer Charity (2007) and the Medical Research Council (2010). In 2011, I was appointed as non-clinical lecturer and I am now Senior Lecturer in the Department of Oncology and Metabolism.
- Research interests
-
Our tea. ‘Nanobug Oncology Sheffield’ (@Nanobug_Shef) focuses on developing state-of-the-art methods to target anticancer therapies to tumours. For example, we have devised a way to use macrophages as ‘trojans’ to deliver large quantities of cancer-killing virus to both primary and secondary tumours simultaneously (click here). We are currently developing innovative nanomedicine platforms to improve the targeting of drugs to tumours so that healthy tissue remains unharmed. We have used these platforms to protect and deliver oncolytic viruses via the bloodstream so that advanced metastatic cancers can be treated. These include liposomes, nanohydrogels, silk fibroin, extracellular vesicles, and magnetic nanoparticles. For the latter, we recently demonstrated that iron particles purified from magnetotactic bacteria were able to shield viruses and guide them to tumours in models of breast cancer. https://www.theguardian.com/science/2022/may/08/magnets-made-by-soil-bacteria-offer-hope-for-breast-and-prostate-cancer
Current projects
- Targeting novel oncolytic viruses to tumours.
- Using nanomagnet technology to improve tumour targeting.
- Developing novel magnetic devices for cancer.
- Using a novel microfluidic device for producing silk fibroin nanoparticles.
- Developing nanoplatforms for targeting oncolytic viruses.
- Characterisation of infiltrating subsets of monocytes/macrophages in the tumour microenvironment.
- Using immune checkpoint inhibitors in combination with oncolytic viruses.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
- TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment response. Theranostics, 12(8), 3584-3600.
- Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology and Medicine, 40. View this article in WRRO
- Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12. View this article in WRRO
- Oncolytic virotherapy treatment of breast cancer : barriers and recent advances. Viruses, 13(6). View this article in WRRO
- Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
- Cell-based tracers as Trojan horses for image-guided surgery. International Journal of Molecular Sciences, 22(2). View this article in WRRO
- Nanoparticles: properties and applications in cancer immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
- Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
- Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells. ACS Biomaterials Science & Engineering, 3(6), 1027-1038. View this article in WRRO
- C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 112(37), 11618-11623. View this article in WRRO
- Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nature Communications, 6(-), ---. View this article in WRRO
- Macrophage-mediated response to hypoxia in disease. Hypoxia, 185-185. View this article in WRRO
Conference proceedings papers
- 233. Biological Roles of C5ORF30 in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, Vol. 53(suppl_1) (pp i147-i147)
All publications
Journal articles
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7), e009368-e009368.
- In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges. Expert Review of Clinical Immunology. View this article in WRRO
- An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy. Medical Research Archives, 12(6).
- Exercise to transform tumours from cold to hot and improve immunotherapy responsiveness. Frontiers in Immunology, 14, 1335256.
- 18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate. ESMO Open, 8(1), 101664-101664.
- Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116.
- Norovirus: an overview of virology and preventative measures. Viruses, 14(12).
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
- TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment response. Theranostics, 12(8), 3584-3600.
- Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology and Medicine, 40. View this article in WRRO
- Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12. View this article in WRRO
- Oncolytic virotherapy treatment of breast cancer : barriers and recent advances. Viruses, 13(6). View this article in WRRO
- Differential effects of zoledronic acid and oestrogen on anti-cancer immunity. Bone Reports, 14, 101024.
- Magnetosomes and magnetosome mimics : preparation, cancer cell uptake and functionalization for future cancer therapies. Pharmaceutics, 13(3).
- Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
- Development of a new hyaluronic acid based redox-responsive nanohydrogel for the encapsulation of oncolytic viruses for cancer immunotherapy. Nanomaterials, 11(1).
- Cell-based tracers as Trojan horses for image-guided surgery. International Journal of Molecular Sciences, 22(2). View this article in WRRO
- Specific targeting of PEGylated liposomal doxorubicin (Doxil®) to tumour cells using a novel TIMP3 peptide. Molecules, 26(1).
- Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25.
- Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
- microRNAs regulating Tribbles-1: potential molecular targets in prostate cancer. European Urology Supplements, 18(8), e3090-e3091.
- Macrophage-associated changes in peri-prostatic adipose tissue; a novel local driver of prostate tumorigenesis?. European Urology Supplements, 18(8), e3060-e3060.
- Nanoparticles: properties and applications in cancer immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
- The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. The Journal of Immunology, 202(4), 1069-1078.
- Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
- Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
- Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells. ACS Biomaterials Science & Engineering, 3(6), 1027-1038. View this article in WRRO
- Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer.. Mediators Inflamm, 2016, 5894347-5894347. View this article in WRRO
- An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of Medicinal Chemistry, 58(23), 9309-9333. View this article in WRRO
- Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. Human Molecular Genetics, 24(19), 5367-5377. View this article in WRRO
- C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 112(37), 11618-11623. View this article in WRRO
- Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 75(17), 3479-3491.
- Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nature Communications, 6(-), ---. View this article in WRRO
- 79. Investigation of the Role of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, 53(suppl_1), i85-i85.
- Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice.. PLoS One, 9(2), e88767. View this article in WRRO
- A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice.. Angiogenesis, 17(1), 207-219. View this article in WRRO
- THU0004 The Role of Histone Deacetylases in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes. Annals of the Rheumatic Diseases, 72(Suppl 3), A165.4-A166.
- THU0107 Hypoxia-Inducible Factor 2A is Preferentially Expressed by M2-Like Synovial Macrophages in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A199.1-A199.
- AB0087 Tissue localisation of acid sensing proteins in synovial biopsies from patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A812.2-A812.
- HYPDXIA-INDUCIBLE FACTOR 2A IS PREFERENTIALLY EXPRESSED BY M2-LIKE SYNOVIAL MACROPHAGES IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 199-199.
- THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES. ANNALS OF THE RHEUMATIC DISEASES, 72, 165-166.
- The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes.. Biochem Soc Trans, 41(3), 783-788.
- Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility. Rheumatology, 52(suppl 1), i56-i94.
- Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Rheumatology, 52(suppl 1), i44-i55.
- Construction of Human Monocyte Derived Macrophages Armed with Oncolytic Viruses. BIO-PROTOCOL, 3(13).
- Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.. Cancer Res, 73(2), 490-495.
- Khat (Catha edulis) alters the phenotype and anti-microbial activity of peripheral blood mononuclear cells.. J Ethnopharmacol, 138(3), 780-787.
- Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.. J Immunol, 186(7), 4183-4190.
- Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.. Cancer Res, 71(8), 2826-2837.
- Use of macrophages to target therapeutic adenovirus to human prostate tumors.. Cancer Res, 71(5), 1805-1815.
- Tumour infiltrating host cells and their significance for hyperthermia.. Int J Hyperthermia, 26(3), 247-255.
- The role of myeloid cells in the promotion of tumour angiogenesis.. Nat Rev Cancer, 8(8), 618-631.
- A novel magnetic approach to enhance the efficacy of cell-based gene therapies.. Gene Ther, 15(12), 902-910.
- The dual immunoregulatory roles of stress proteins.. Trends Biochem Sci, 33(2), 71-79.
- A non-receptor-mediated mechanism for internalization of molecular chaperones.. Methods, 43(3), 238-244.
- Administration of the stress protein gp96 prolongs rat cardiac allograft survival, modifies rejection-associated inflammatory events, and induces a state of peripheral T-cell hyporesponsiveness.. Cell Stress Chaperones, 12(1), 71-82.
- Analysis of purified gp96 preparations from rat and mouse livers using 2-D gel electrophoresis and tandem mass spectrometry.. Biochimie, 88(9), 1165-1174.
- The stress protein gp96 is not an activator of resting rat bone marrow-derived dendritic cells, but is a costimulator and activator of CD3+ T cells.. Cell Stress Chaperones, 11(4), 364-378.
- Identification of a rat bone marrow-derived dendritic cell population which secretes both IL-10 and IL-12: evidence against a reciprocal relationship between IL-10 and IL-12 secretion.. Immunobiology, 211(5), 391-402.
- Gp96 prolongs rat cardiac allograft survival and modifies rejection-associated inflammatory events. IMMUNOLOGY, 116, 107-107.
- The stress protein gp96 does not activate rat bone marrow-derived dendritic cells. IMMUNOLOGY, 116, 98-98.
- Hypoxia regulates macrophage functions in inflammation.. J Immunol, 175(10), 6257-6263.
- Heat shock proteins and allograft rejection.. Contrib Nephrol, 148, 122-134.
- Systematic evaluation of the conditions required for the generation of immature rat bone marrow-derived dendritic cells and their phenotypic and functional characterization.. J Immunol Methods, 294(1-2), 165-179.
- Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.. Immunology, 109(1), 41-48.
- Pilot study: Immunisation with melanoma associated peptides and GM-CSF in HLA-A2 patients with metastatic melanoma.. BRIT J CANCER, 86, S115-S115.
- Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.. Cancer Res, 60(22), 6441-6447.
- Proliferating Cell Nuclear Antigen in the Era of Oncolytic Virotherapy. Viruses, 16(8), 1264-1264.
- Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy. Pharmaceutics, 15(7), 1811-1811.
- Are mild cleansers appropriate for hand hygiene in the COVID era? An in vitro investigation of the antiviral efficacy of different hand hygiene products. Frontiers in Virology, 3, 1180815.
- HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models. Viruses, 15(3), 603-603.
- Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
- Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?. Viruses, 14(7), 1493-1493.
- Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Frontiers in Molecular Biosciences, 9.
- TRIB1 regulates tumour growth via controlling tumour-associated macrophage phenotypes and is associated with breast cancer survival and treatment response.
- Macrophage-mediated response to hypoxia in disease. Hypoxia, 185-185. View this article in WRRO
- Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.
Chapters
- Oncolytic viral particle delivery, Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
- The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy, Tumor Immunology and Immunotherapy (pp. 43-62). Oxford University Press
- Role of Tumour-Associated Macrophages in the Regulation of Angiogenesis, Tumour-Associated Macrophages (pp. 17-29). Springer New York
- The Pro- and Anti-Inflammatory Properties of the Stress Protein GP96, Heat Shock Proteins: Potent Mediators of Inflammation and Immunity (pp. 309-320). Springer Netherlands
- Immunoregulatory Activities of Extracellular Stress Proteins, Cell Stress Proteins (pp. 377-395). Springer New York
- Silk Fibroin Nanoparticles: A Biocompatible Multi-Functional Polymer for Drug Delivery, Biomedical Engineering IntechOpen
- Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer, Liposomes - Recent Advances, New Perspectives and Applications [Working Title] IntechOpen
Conference proceedings papers
- 2302P Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays. Annals of Oncology, Vol. 34 (pp S1177-S1177)
- Abstract 2797: Changes in the phenotype of macrophages and CD8+ T Cells in the perivascular niche of prostate tumours following androgen deprivation. Tumor Biology
- Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
- Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer
- Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
- Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
- Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
- Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
- Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
- Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
- Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
- Breast cancer immunotherapy using magnetised oncolytic viruses. European Journal of Cancer, Vol. 92 (pp S4-S4)
- Hypoxia-induced changes in astrocytes and their role in the formation of age-associated white matter lesions. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 44 (pp 17-18)
- The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages. ARTHRITIS & RHEUMATOLOGY, Vol. 69
- Abstract 2938: Tumour-associated macrophage polarisation and re-education with oncolytic viruses. Tumor Biology
- OP0134 The Rheumatoid Arthritis Susceptibility Gene C5ORF30 Acts as An Immunomodulator in Macrophages. Annals of the Rheumatic Diseases, Vol. 75(Suppl 2) (pp 107.1-107)
- Development of a Trojan horse oncolytic virus for treatment of myeloma.. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e14035-e14035)
- OP0296 Hypoxia-Inducible Factor 2A Regulates Macrophage Function in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 174.2-174)
- THU0515 C5orf30 A Novel Regulator of Tissue Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 361.3-361)
- FRI0360 Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis Synovial Fibroblasts. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 517.2-517)
- 233. Biological Roles of C5ORF30 in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, Vol. 53(suppl_1) (pp i147-i147)
- INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 85-85)
- BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 147-147)
- Acidification enhances acid sensing protein and matrix metalloproteinase expression in human rheumatoid fibroblast like synoviocytes. Annals of the Rheumatic Diseases, Vol. 73(Supplement 2) (pp 511-511)
- THU0080 The Role of C5ORF30 in Rheumatoid Arthritis Pathogenesis. Annals of the Rheumatic Diseases, Vol. 72(Suppl 3) (pp A190.2-A190)
- The biological role of C5orf30 in rheumatoid arthritis pathogenesis. IMMUNOLOGY, Vol. 140 (pp 45-45)
- Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1232-S1233)
- Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1035-S1036)
- Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 94(5) (pp A3-A3)
- TISSUE LOCALISATION OF ACID SENSING PROTEINS IN SYNOVIAL BIOPSIES FROM PATIENTS WITH RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 812-812)
- THE ROLE OF C5ORF30 IN RHEUMATOID ARTHRITIS PATHOGENESIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 190-190)
- BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 52 (pp 50-50)
- INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 52 (pp 79-80)
- MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR-2. RHEUMATOLOGY, Vol. 52 (pp 78-78)
- Biological Roles of C5orf30 in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
- Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
- Acid sensing protein genes are expressed in human rheumatoid-derived synoviocytes. BONE, Vol. 50 (pp S191-S191)
- C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S719-S719)
- Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. DRUG DISCOVERY TODAY, Vol. 15(23-24) (pp 1097-1098)
- Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. HUMAN GENE THERAPY, Vol. 21(4) (pp 488-488)
- Magnetite nanoparticle-loaded macrophages enhance gene delivery to tumours. IMMUNOLOGY, Vol. 120 (pp 82-82)
- Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, Vol. 66(8)
Other
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
Preprints
- Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.
- Teaching interests
-
I teach Immunology on the MBChB course and I am module lead for Phase 2a immunology. I also deliver the cell-based therapies, Gene Therapy, Animal models in Research and Tumour Immunology lectures for the medical school MSc. Molecular Medicine, MSc. Translational Oncology, MSc. Advanced Cell and Gene therapy, MSc Translational Neuroscience.
- Professional activities and memberships
-
- American Association of Cancer Research (AACR).
- British Society of Immunology (BSI).
- European Macrophage and Dendritic Cell Society and British Society of Immunology.